Last reviewed 2026-05-14 · How we verify

Dexmedetomidine (DEX)

Dexmedetomidine (DEX) is a Alpha-2 adrenergic receptor agonist Small molecule drug developed by Ain Shams University. It is currently FDA-approved for Sedation of intubated and mechanically ventilated patients in intensive care units, Sedation and analgesia for procedural sedation, Perioperative anxiolysis and sedation.

Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system.

Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system. Used for Sedation of intubated and mechanically ventilated patients in intensive care units, Sedation and analgesia for procedural sedation, Perioperative anxiolysis and sedation.

At a glance

Mechanism of action

By binding to alpha-2 adrenergic receptors, dexmedetomidine reduces norepinephrine release and enhances inhibitory neurotransmission, leading to sedation without respiratory depression. It also provides analgesic and anxiolytic effects through spinal and supraspinal mechanisms. The drug maintains a relatively preserved airway reflex and allows patients to be aroused, distinguishing it from other sedatives.

Approved indications

• Sedation of intubated and mechanically ventilated patients in intensive care units
• Sedation and analgesia for procedural sedation
• Perioperative anxiolysis and sedation

Common side effects

• Hypotension
• Bradycardia
• Hypertension (transient, initial)
• Dry mouth
• Rebound hypertension on withdrawal

Key clinical trials

• Effect of Lidocaine Infusion Versus Dexmedemidine Infusion on the Neurocognitive Function of Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography(ERCP): a Randomized, Controlled Trial. (NA)
• The Effect of Dexmedetomidine Infusion Alone Versus the Combination of Dexmedetomidine and Melatonin on Reduction of Post-operative Delirium (POD) After Open Brain Surgeries (PHASE4)
• Early Dexmedetomidine and Sympathetic Regulation in Sepsis (PHASE4)
• Study of the Efficacy of Moderate Sedation With Intra-NAsal Dexmedetomidine Monitored by EEG MOnitoring (NA)
• Intrathecal Bupivacaine With or Without Dexmetomidine for Cesserian Delivery (PHASE2)
• Effect of Dexmedetomidine Dosage on Postoperative Delirium in Geriatric Orthopedic Surgery (PHASE2)
• Efficacy of Non-weight Based, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks (PHASE1, PHASE2)
• Perioperative Multimodal Analgesia Protocol for Supratentorial Craniotomy (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Dexmedetomidine (DEX) CI brief — competitive landscape report
• Dexmedetomidine (DEX) updates RSS · CI watch RSS
• Ain Shams University portfolio CI

Frequently asked questions about Dexmedetomidine (DEX)

Related

• Drug class: All Alpha-2 adrenergic receptor agonist drugs
• Target: All drugs targeting Alpha-2 adrenergic receptor
• Manufacturer: Ain Shams University — full pipeline
• Therapeutic area: All drugs in Anesthesia and Critical Care
• Indication: Drugs for Sedation of intubated and mechanically ventilated patients in intensive care units
• Indication: Drugs for Sedation and analgesia for procedural sedation
• Indication: Drugs for Perioperative anxiolysis and sedation

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing